94 related articles for article (PubMed ID: 6949877)
1. Clinical evaluation of NCA in patients with chronic myelocytic leukemia.
Wahren B; Gahrton G; Rudén U; Hammarström S
Int J Cancer; 1982 Feb; 29(2):133-7. PubMed ID: 6949877
[TBL] [Abstract][Full Text] [Related]
2. An investigation of factors influencing serum NCA (non-specific cross-reacting antigen) level in patients with chronic myeloid leukaemia.
Frénoy N; Ben-Bunant M; Berruel C; Child JA; Gendron MC; Missett JL; Razafimahaleo E; Burtin P
Br J Cancer; 1982 Nov; 46(5):765-72. PubMed ID: 6756460
[TBL] [Abstract][Full Text] [Related]
3. Presence of NCA (nonspecific cross-reacting antigen) in the cells of the human granulocyte series.
Burtin P; Flandrin G; Fondaneche MC
Blood Cells; 1980; 6(2):263-78. PubMed ID: 6991029
[TBL] [Abstract][Full Text] [Related]
4. Expression of nonspecific cross-reacting antigen species in myeloid leukemic patients and healthy subjects.
Noworolska A; Harłozińska A; Buchegger F; Lawińska B; Richter R
Blut; 1989 Feb; 58(2):69-73. PubMed ID: 2920218
[TBL] [Abstract][Full Text] [Related]
5. Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series.
Noworolska A; Harłozińska A; Richter R; Brodzka W
Br J Cancer; 1985 Mar; 51(3):371-7. PubMed ID: 3882113
[TBL] [Abstract][Full Text] [Related]
6. Decrease of a normal colon and granulocyte antigen (NCA) in whole lysed blood of myelosuppressed patients.
Gadler F; Wahren B
Scand J Haematol; 1983 Apr; 30(4):297-302. PubMed ID: 6687956
[TBL] [Abstract][Full Text] [Related]
7. Non-specific cross-reacting antigen serum concentration in myeloid leukemias.
Frénoy N; Burtin P
Clin Chim Acta; 1980 Apr; 103(1):23-31. PubMed ID: 6930335
[TBL] [Abstract][Full Text] [Related]
8. Serum NCA in bone marrow transplant recipients and its metabolism.
Gadler F; Wahren B
Med Oncol Tumor Pharmacother; 1985; 2(4):281-5. PubMed ID: 3910975
[TBL] [Abstract][Full Text] [Related]
9. Distribution of surface nonspecific cross-reacting antigen and influence of proteolytic enzymes on this antigen in myeloid cell series.
Noworolska A; Harłozińska-Szmyrka A; Richter R
Cancer Detect Prev; 1986; 9(3-4):365-71. PubMed ID: 3527416
[TBL] [Abstract][Full Text] [Related]
10. Relationship between myelomonocytic, myeloid and nonspecific cross-reacting (NCA) antigens during myelocytic cell differentiation.
Harłozińska A; Noworolska A; Majdic O; Richter R; Kotlarek-Haus S
Br J Cancer; 1987 Dec; 56(6):787-90. PubMed ID: 2449236
[No Abstract] [Full Text] [Related]
11. [Origin and significance of a thermostable granulocyte antigen].
Hahn P; Fischer H; Häntzschel H; Thoss K
Z Gesamte Inn Med; 1984 Feb; 39(4):63-7. PubMed ID: 6375174
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of cationic proteins of leukocyte lysosomes: cationic leukocyte antigen (CLA) as a marker of blast crisis in chronic myelocytic leukaemia (author's transl)].
Tischendorf FW; Wüst I; Tischendorf MM
Klin Wochenschr; 1977 Jul; 55(14):685-93. PubMed ID: 268450
[TBL] [Abstract][Full Text] [Related]
13. Regulation of bone marrow myeloblast proliferation in chronic myeloid leukemia.
Stryckmans P; Debusscher L; Socquet M
Cancer Res; 1976 Sep; 36(9 pt.1):3034-8. PubMed ID: 1067897
[TBL] [Abstract][Full Text] [Related]
14. Myeloid antigens and antigen densities in mice and men.
Jäger G; Hoffmann-Fezer G; Rodt H; Huhn D; Thiel E; Thierfelder S
Haematol Blood Transfus; 1977; 20():109-16. PubMed ID: 273001
[No Abstract] [Full Text] [Related]
15. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
Lanza F; Bi S; Castoldi G; Goldman JM
Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192
[TBL] [Abstract][Full Text] [Related]
16. Distribution of carbohydrate structures in individual maturation stages of myeloid leukemic cells.
Noworolska A; Slesak B; Harłonzińska A; Richter R
Neoplasma; 1991; 38(1):57-62. PubMed ID: 2011210
[TBL] [Abstract][Full Text] [Related]
17. Agglutination of granulocytes from chronic myeloid leukaemia by concanavalin A.
Bhisey AN; Rao SG; Advani SH; Ray V
Acta Haematol; 1980; 63(4):211-6. PubMed ID: 6771951
[TBL] [Abstract][Full Text] [Related]
18. [An evaluation of the prognostic significance of antigen CD95(Fas/APO-1) expression on the cells of patients with a myelodysplastic syndrome, acute myeloid leukemia and chronic myeloleukemia].
Polosukhina ER; Kuznetsov SV; Logcheva NP; Zabotina TN; Tenuta MR; Shirin AD; Kaletin GI; Turkina AG; Tsvetaeva NV; Shishkin IuV; Kadagidze ZG; Khoroshko ND; Volkova MA; Baryshnikov AIu
Ter Arkh; 1998; 70(7):21-5. PubMed ID: 9742630
[TBL] [Abstract][Full Text] [Related]
19. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
Andreasen RB; Olsson L
J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
[TBL] [Abstract][Full Text] [Related]
20. Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors.
Aglietta M; Piacibello W; Stacchini A; Dezza L; Sanavio F; Malavasi F; Infelise V; Resegotti L; Gavosto F
Cancer Res; 1986 Apr; 46(4 Pt 1):1783-7. PubMed ID: 3456268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
